Skip to content

Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma

Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03132649
Enrollment
300
Registered
2017-04-28
Start date
2017-03-15
Completion date
2019-06-01
Last updated
2018-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hilar Cholangiocarcinoma

Keywords

Three dimensional visualization, Operation strategy

Brief summary

The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

Detailed description

Because of the complexity of hilar cholangiocarcinoma,the limitations of 2D images of CT/MRI and the uncertainty of surgeons'experience, it is difficult for the surgeons to diagnosis and assess the operation strategy accurately based on traditional 2D imaging(CT/MRI).The aim of the multi-centre study is to evaluate correctly the impact of three-dimensional visualization on operation strategy and complications for hilar cholangiocarcinoma.

Interventions

None listed

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. 18 years≤ Age ≤70 years 2. Complying with the diagnosis criteria of hilar cholangiocarcinoma. 3. Without intrahepatic or extrahepatic extensive cancer metastasis. 4. Preoperative serum bilirubin ≤51.3 umol/L or preoperative serum bilirubin \< 200 umol/L after the drainage by PTCD(percutaneous transhepaticcholangial drainage)/ENBD(endoscopic nasobiliary drainage). 5. The patients are volunteered for the study.

Exclusion criteria

1. Patients with mental illness. 2. Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.) 3. The patients refused to take part in the study. 4. There are other co-existed malignant tumors.

Design outcomes

Primary

MeasureTime frameDescription
Impact on operation strategy of three-dimensional visualization technique2 yearFirstly, the operation strategies based on original CT or MRI image data will be made by the team, Secondly, the operation strategies based on three dimensional reconstruction models will be made by the team, then, actually surgical strategies will be recorded. The change of operation strategy will be assessed by comparing the strategy of the 2D model and 3D model. The change rate of operation strategy will be recorded and presented as percentage.
Impact on complications of three-dimensional visualization technique2 yearThe complications are refer to the classification of Clavien-Dindo, including postoperative bleeding, biliary fistula, ascites, postoperative liver failure, renal dysfunction, pleural effusion, abdominal cavity infection, abdominal abscess, incision infection, the occurrence cases of each complications (number) will be recorded.

Secondary

MeasureTime frameDescription
Stool Routine (the 1th, 3 th,5th, 7th)2 yearDefecate occult blood test, Microorganisms (mold, parasites, etc.)
Blood biochemistry (the 1th, 3 th,5th, 7th)2 yearSerum albumin(g/L), serum pre-albumin(g/L), serum globulin(g/L), total bilirubin(µmol/L), direct bilirubin(µmol/L),serum glutamic-oxaloacetic transaminase (AST, IU/L), serum glutamic pyruvic transaminase (ALT, IU/L), alkaline phosphatase (ALP, IU/L), gamma glutamyl transpeptidase(r-GGT, IU/L) ,Serum creatinine(µmol/L), Urea(mmol/L), Blood sugar(mmol/L)
Tumor marker2 yearAlpha fetoprotein(AFP, ng/L), Carbohydrate antigen-199(CA-199, ku/L), Carbohydrate antigen-125(CA-125, ku/L), Carcinoembryonic antigen (CEA, ng/L), Carbohydrate antigen-153(CA-153, ku/L)
The blood coagulation function (the 1th, 3th, 5th, 7th)2 yearprothrombin time (PT, s), partial thromboplastin time (APTT), international normalized ratio (INR), plasma prothrombin activity (PTA, %), fibrinogen (FIB, g/L), d-dimer(mg/L)
Blood routine examination (the 1th, 3 th, 5th, 7th)2 yearHemoglobin(g/L), Platelet(109/L), and neutrophilic granulocyte percentage (%)
Preoperative viral loading2 yearHBV(hepatitis B virus)- DNA、HCV(hepatitis C virus)- RNA
Postoperative results of paraffin wax and immunohistochemical index2 yearCK7、CK18、CK19、Hepatocyte、CD34(vascular)、S-100(nerve)、D2-40(lymphatic)、AFP、Ki67
Postoperative pathologic examination2 yearThe stage of TNM, The condition of resection (R0/R1/R2), the condition of liver cirrhosis, the pathological type of the tumor (Nipple type/nodule type/infiltration type)
Inflammatory biomarkers2 yearC-reactive protein, procalcitonin
Urine routines (the 1th, 3 th,5th, 7th)2 yearUrine specific gravity, urine protein(mg/dl), urine sugar(mmol/L), leukocytes in urine(number/ul), urine erythrocyte(number/ul)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026